Lubrizol announced that its LifeSciences business has expanded its global development and manufacturing facilities, and the latest investment is a new medical device applications lab in Brecksville, OH, USA. This lab features applications testing, small-scale compounding as well as injection moulding for long-term implantables. The 1,800-square foot facility will also focus on accelerated R&D, from polymers to device scale up and testing in a short period of time, said the company.
According to Lubrizol, the medical device applications lab is a substantial piece of LifeSciences‘ full-service capabilities. The business is a medical device development partner, helping customers from concept to commercialisation by offering polymer customisation, drug-eluting device development and contract manufacturing services. The business also has a strong presence in the interventional catheter, long-term implant and drug-eluting device markets, said the company. In addition, the business recently launched new dexamethasone-loaded polymers designed to minimise inflammation and help ensure the success of implantable medical devices.
“The new applications lab is another commitment to healthcare companies looking for a full-service development partner. We continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth,” said Uwe Winzen, general manager, Lubrizol LifeSciences. “When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process.”